About
Euclises develops targeted cancer therapies that disrupt the tumor microenvironment to prevent tumor immune evasion, focusing on selecting patients likely to respond to immuno-oncology treatments and optimizing dosage for efficacy.
Explore Euclises's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.